Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18-36
SponsorHopital Foch
About this trial
Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.
Eligibility criteria
Qualifiers
Women aged 18 to 36 years (women ≥18 years to <36 years) with endometriosis and / or adenomyosis
Having benefited from In vitro fertilisation /intracytoplasmic micro-injection with freeze all and for whom the frozen embryon transfer of a blastocyst is planned
A normal uterine cavity
An MRI showing endometriosis and / or adenomyosis during the inclusion visit
Disqualifiers
Patient aged <18 years and ≥ 36 years
BMI> 35
History of implantation failures (≥ 2)
Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra
Trial design
Treatments tested in this trial
- GnRH agonist
Treatment groups
180 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov